ReviewTherapeutic advances in urology
A review of optimal prostate biopsy: indications and techniques.
Review in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison ofFrontiers in oncology · 2024Pooled it
- Transperineal (TP) Versus Transrectal (TR) Prostate Biopsy: Efficacy, Safety, and Systemic Challenges-A Narrative Review.Journal of clinical medicine · 2026Review
- Novel Strategy for Acquiring Metabolically-Tagged Nascent Extracellular Vesicles: Implications for Identifying Surface Protein Markers of Extracellular Vesicles From Neuroblastoma Cells Cultured With Native Serum.Journal of extracellular vesicles · 2025Article
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Article
- Prostate biopsy in patients without rectal access: a systematic review and proportional meta-analysis.Central European journal of urology · 2025Review
- Article
- The role of urology and radiology in prostate biopsy: current trends and future perspectives.World journal of urology · 2024Review
- Current Approach to Complications and Difficulties during Transrectal Ultrasound-Guided Prostate Biopsies.Journal of clinical medicine · 2024Review
- Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy.Exploration of targeted anti-tumor therapy · 2024Review
- Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.JAMA network open · 2023Article
- Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.Cancers · 2023Review
- New transperineal ultrasound-guided biopsy for men in whom PSA is increasing after Miles' operation.Insights into imaging · 2023Article
- Pilot study for generating and assessing nomograms and decision curves analysis to predict clinically significant prostate cancer using only spatially registered multi-parametric MRI.Frontiers in oncology · 2023Article
- The past and present of prostate cancer and its treatment and diagnostics: A historical review.SAGE open medicine · 2023Review
- Feasibilities and outcomes of patients treated with simultaneous prostate biopsy and general urological surgeries.Experimental and therapeutic medicine · 2023Article
- Occurrence and significance of fluoroquinolone-resistant and ESBL-producingJAC-antimicrobial resistance · 2022Article
- Infection complications after transrectal ultrasound-guided prostate biopsy: A radiology department's experience and strategy for improvement.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- A smart, practical, deep learning-based clinical decision support tool for patients in the prostate-specific antigen gray zone: model development and validation.Journal of the American Medical Informatics Association : JAMIA · 2022Article
- Image-guided Raman spectroscopy navigation system to improve transperineal prostate cancer detection. Part 2: in-vivo tumor-targeting using a classification model combining spectral and MRI-radiomics features.Journal of biomedical optics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate biopsy is the gold standard diagnostic technique for the detection of prostate cancer. Patient selection for prostate biopsy is complex and is influenced by emerging use of prebiopsy imaging. The introduction of the magnetic resonance imaging (MRI)-transrectal ultrasound (TRUS) fusion prostate biopsy has clear advantages over the historical standard of care. There are several biopsy techniques currently utilized with unique advantages and disadvantages. We review and summarize the current body of literature pertaining to when and how a prostate biopsy should be performed. We discuss current recommendations regarding patient selection for biopsy and discuss future directions regarding prebiopsy imaging. We offer a description of the MRI-TRUS fusion biopsy technique and a comparison of many of the currently available fusion software platforms. Articles pertaining to the title were obtained via PubMed index search with relevant keywords supplemented with personal collection of related publications. Prostate biopsy should be considered for patients with gross digital rectal exam (DRE) abnormality, patients with a prostate-specific antigen (PSA) greater than 4 ng/ml, and concomitant risk factors for prostate cancer or patients with lesions identified on multiparametric MRI (mpMRI) with Prostate Imaging Reporting and Data System 2 (PI-RADS2) score of 4 or 5. MRI-TRUS fusion biopsy has demonstrated advantages in cancer detection when compared with TRUS-guided biopsy. There are currently several fusion software platforms available with a variety of biopsy approaches. Future efforts should detail the role of prebiopsy imaging as a triage tool for prostate biopsy. Consensus should be sought regarding the preferred modality of fusion biopsy. Additional data describing each fusion software platform would enable a more rigorous comparison of platform sensitivities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.